For research use only. Not for therapeutic Use.
Mutant IDH1 inhibitors（Cat No.:I001646）are a class of targeted therapies designed to block the activity of mutant isocitrate dehydrogenase 1 (IDH1), an enzyme frequently mutated in various cancers, particularly gliomas and acute myeloid leukemia (AML). Mutant IDH1 produces an oncometabolite, 2-hydroxyglutarate (2-HG), which promotes tumorigenesis. By inhibiting mutant IDH1, these inhibitors reduce 2-HG levels, potentially reversing the aberrant metabolic state of cancer cells. This approach has shown promise in clinical trials, with compounds like ivosidenib offering hope for targeted treatments in IDH1-mutant cancers, improving patient outcomes and survival rates.
| Catalog Number | I001646 |
| CAS Number | 1429180-08-4 |
| Synonyms | (S)-3-(2-(((S)-1-(4-((4-acetylpiperazin-1-yl)methyl)phenyl)ethyl)amino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one |
| Molecular Formula | C25H34N6O3 |
| Purity | ≥95% |
| Target | Isocitrate Dehydrogenase (IDH) |
| Solubility | DMSO: ≥ 34 mg/mL |
| Storage | Store at -20C |
| IC50 | 72 nM |
| IUPAC Name | (4S)-3-[2-[[(1S)-1-[4-[(4-acetylpiperazin-1-yl)methyl]phenyl]ethyl]amino]pyrimidin-4-yl]-4-propan-2-yl-1,3-oxazolidin-2-one |
| InChI | InChI=1S/C25H34N6O3/c1-17(2)22-16-34-25(33)31(22)23-9-10-26-24(28-23)27-18(3)21-7-5-20(6-8-21)15-29-11-13-30(14-12-29)19(4)32/h5-10,17-18,22H,11-16H2,1-4H3,(H,26,27,28)/t18-,22+/m0/s1 |
| InChIKey | BEWLUEOYYPKPQL-PGRDOPGGSA-N |
| SMILES | C[C@@H](C1=CC=C(C=C1)CN2CCN(CC2)C(=O)C)NC3=NC=CC(=N3)N4[C@H](COC4=O)C(C)C |
| Reference | <p style=/line-height:25px/> |
